All studies were approved by the Institutional Animal Care and Use Committee. In rat experiments, Pirc males at 5 months of age were assigned to study groups (3–4/group). Rats were then treated for 2 months with test agents, as follows: 6-SFN, 10 mg/kg body weight via daily oral gavage (p.o.); JQ1, 10 mg/kg body weight via twice weekly intraperitoneal (i.p.) injection; 6-SFN + JQ1 at the doses of the individual compounds, or vehicle. At the end of the study, colon polyps were enumerated, and tissues were bio-banked for molecular analyses, as reported [13 (link),33 (link),36 (link)].
Xenograft experiments were done as previously described [13 (link)]. Briefly, SW620 cells (5 × 106) were injected into either flank of male athymic nude mice (Envigo, Indianapolis, IN, USA). After a week, animals were randomized to treatment groups, as follows (n = 5 mice/group): BG45, 50 mg/kg body weight; dBET6, 7.5 mg/kg body weight, thrice weekly i.p. injections for 4 weeks; BG45 + dBET6, at the doses of the individual compounds, or vehicle. Tumor volumes were measured twice per week using Vernier calipers.
Xenograft experiments were done as previously described [13 (link)]. Briefly, SW620 cells (5 × 106) were injected into either flank of male athymic nude mice (Envigo, Indianapolis, IN, USA). After a week, animals were randomized to treatment groups, as follows (n = 5 mice/group): BG45, 50 mg/kg body weight; dBET6, 7.5 mg/kg body weight, thrice weekly i.p. injections for 4 weeks; BG45 + dBET6, at the doses of the individual compounds, or vehicle. Tumor volumes were measured twice per week using Vernier calipers.
Free full text: Click here
